Sientra Receives Innovative Technology Contract from Vizient for AlloX2® Tissue Expander
Sientra, Inc. (NASDAQ: SIEN) announced the AlloX2 tissue expander has been awarded an Innovative Technology contract from Vizient, Inc., effective May 1, 2021. This contract signifies the AlloX2's unique qualities that enhance clinical care and patient safety. The AlloX2 features a dual-port design allowing less invasive draining of fluids, which aids in quicker treatment responses and potentially reduces reoperation rates. With this award, AlloX2 is now accessible to over 50% of the U.S. acute care providers, marking a critical step in expanding its market presence.
- Awarded Innovative Technology contract by Vizient, enhancing credibility.
- AlloX2's dual-port design allows for non-invasive draining, improving patient care.
- Now available to over 50% of the nation's acute care providers.
- None.
Contract recognizes products that bring improvements to the health care industry
SANTA BARBARA, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced its AlloX2 tissue expander has been awarded an Innovative Technology contract from Vizient, Inc., the nations’ largest member-driven health care performance improvement company. The contract went into effect May 1 and signifies to Vizient members the AlloX2’s unique qualities that potentially bring improvement to the health care industry.
Innovative Technology contracts are awarded based on the recommendations of health care experts serving on a Vizient member-led council who review product submissions through Vizient’s Innovative Technology Program. Councils identify technologies that have the potential to enhance clinical care, patient safety, health care worker safety or improve business operations of health care organizations.
Sientra’s AlloX2’s one of a kind dual-port design allows for less invasive, non-surgical draining of serous fluids. The AlloX2 is the only tissue expander on the market with an integral drain providing direct access to the periprosthetic space where fluid can accumulate. This allows for diagnostic fluid sampling to enable a faster treatment response. The AlloX2 was innovatively designed to mitigate risks associated with breast expansion and ultimately reduce reoperation rates.
“We are delighted to receive an Innovative Technology contract, as it highlights the importance of the transformative technology in our AlloX2 product,” said Ron Menezes, President and Chief Executive Officer of Sientra. “Vizient serves more than
“After reviewing feedback on AlloX2 at our Innovative Technology Exchange, our member council agreed this solution deserves the Innovative Technology contract. Congratulations to Sientra on receiving this status,” said Debbie Archer, Director of Procurement and Vizient Innovative Technology Program leader.
Vizient represents a diverse membership that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers and represents more than
About Sientra
Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company uniquely focused on plastic surgeons. The Company mission is to offer proprietary innovations and unparalleled partnerships that radically advance how plastic surgeons think, work and care for their patients. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company’s Breast Products Segment includes its Sientra round and shaped breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology, and BIOCORNEUM®, the #1 performing, preferred and recommended scar gel of plastic surgeons(*). The Company’s miraDry Segment, comprised of its miraDry® system, is approved for sale in over 56 international markets and is the only non-surgical, FDA-cleared device indicated for the permanent reduction of underarm sweat and hair and may also reduce odor.
Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company’s investor relations website at www.sientra.com.
(*) Data on file
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, based on management’s current assumptions and expectations of future events and trends, which affect or may affect Sientra’s business, strategy, operations or financial performance, and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are made only as of the date of this release. The words ‘‘believe,’’ ‘‘may,’’ ‘‘might,’’ ‘‘could,’’ ‘‘will,’’ ‘‘aim,’’ ‘‘estimate,’’ ‘‘continue, ‘‘anticipate,’’ ‘‘intend,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘position,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Forward-looking statements may include information concerning the impact of the COVID-19 pandemic on the Company’s business, the timing of the easing of COVID-19 restrictions, future popularity of breast reconstruction procedures, and the ability of Sientra to pull through into hospitals and surgery centers. Such statements are subject to risks and uncertainties, including the continuing popularity breast reconstruction procedures, Sientra’s ability to recapture delayed procedures resulting from the COVID-19 pandemic, the positive reaction from plastic surgeons and their patients to Sientra’s Breast Products, the positive reaction from plastic surgeons and patients to Sientra’s marketing, sales and educational programs, and the ability to execute on the Company’s commercial, product development and manufacturing initiatives, and the ability of Sientra to obtain contracts with hospitals and surgery centers. Additional factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Sientra’s public filings with the Securities and Exchange Commission. All statements other than statements of historical fact are forward-looking statements. The words ‘‘believe,’’ ‘‘may,’’ ‘‘might,’’ ‘‘could,’’ ‘‘will,’’ ‘‘aim,’’ ‘‘estimate,’’ ‘‘continue, ‘‘anticipate,’’ ‘‘intend,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘position,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, and such estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in the Company’s business.
Investor Relations Contact
Leigh Salvo
ir@sientra.com
FAQ
What is the significance of the Innovative Technology contract awarded to Sientra's AlloX2?
How does the AlloX2 tissue expander improve patient care?
What percentage of U.S. acute care providers now have access to Sientra's AlloX2?
When did the Innovative Technology contract for AlloX2 take effect?
